 The purpose of this trial is to assess the effectiveness of Aranesp administered at 300 mcg every 3 weeks q3w in achieving therapeutic objectives of anemia treatment achieving and maintaining hemoglobin levels consistent with the National Comprehensive Cancer Network NCCN guidelines. 